Construction of a Nano-Controlled Release Methotrexate Delivery System for the Treatment of Rheumatoid Arthritis by Local Percutaneous Administration

A drug delivery system was specifically designed for the treatment of rheumatoid arthritis (RA) by local percutaneous administration and the nano-controlled release of methotrexate (MTX). The release behavior of MTX from the synthesized MTX-mSiO<sub>2</sub>@PDA system was investigated in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tingting Guo, Xu Kang, Sifan Ren, Xianjin Ouyang, Mingming Chang
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	methotrexate local percutaneous administration polydopamine pH-sensitive rheumatoid arthritis Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/6fcdfd0277584f1dad57dd24216c4a7d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6fcdfd0277584f1dad57dd24216c4a7d
record_format	dspace
spelling	oai:doaj.org-article:6fcdfd0277584f1dad57dd24216c4a7d2021-11-25T18:29:59ZConstruction of a Nano-Controlled Release Methotrexate Delivery System for the Treatment of Rheumatoid Arthritis by Local Percutaneous Administration10.3390/nano111128122079-4991https://doaj.org/article/6fcdfd0277584f1dad57dd24216c4a7d2021-10-01T00:00:00Zhttps://www.mdpi.com/2079-4991/11/11/2812https://doaj.org/toc/2079-4991A drug delivery system was specifically designed for the treatment of rheumatoid arthritis (RA) by local percutaneous administration and the nano-controlled release of methotrexate (MTX). The release behavior of MTX from the synthesized MTX-mSiO<sub>2</sub>@PDA system was investigated in vitro and in vivo. The obtained results show that after 48 h, twice as much MTX (cumulative amount) is released at pH 5.5 than at pH 7.4. This suggests that the MTX-mSiO<sub>2</sub>@PDA system exhibits a good pH sensitivity. In vitro local percutaneous administration experiments revealed that the cumulative amount of MTX transferred from MTX-mSiO<sub>2</sub>@PDA to pH 5.0 receptor fluid through the whole skin was approximately three times greater than the amount transferred to pH 7.4 receptor fluid after 24 h. Moreover, in vivo experiments conducted on a complete induced arthritis (CIA) model in DBA/1 mice demonstrated that the thickness of a mouse’s toes decreases to nearly 65% of the initial level after 27 days of local percutaneous MTX-mSiO<sub>2</sub>@PDA administration. Compared to the mice directly injected with MTX, those administered with MTX-mSiO<sub>2</sub>@PDA by local percutaneous application exhibit much lower toe thickness deviation, which indicates that the latter group experiences a better cure stability. Overall, these results demonstrate that the local percutaneous administration of MTX delivery systems characterized by nano-controlled release may play an important role in RA therapy.Tingting GuoXu KangSifan RenXianjin OuyangMingming ChangMDPI AGarticlemethotrexatelocal percutaneous administrationpolydopaminepH-sensitiverheumatoid arthritisChemistryQD1-999ENNanomaterials, Vol 11, Iss 2812, p 2812 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	methotrexate local percutaneous administration polydopamine pH-sensitive rheumatoid arthritis Chemistry QD1-999
spellingShingle	methotrexate local percutaneous administration polydopamine pH-sensitive rheumatoid arthritis Chemistry QD1-999 Tingting Guo Xu Kang Sifan Ren Xianjin Ouyang Mingming Chang Construction of a Nano-Controlled Release Methotrexate Delivery System for the Treatment of Rheumatoid Arthritis by Local Percutaneous Administration
description	A drug delivery system was specifically designed for the treatment of rheumatoid arthritis (RA) by local percutaneous administration and the nano-controlled release of methotrexate (MTX). The release behavior of MTX from the synthesized MTX-mSiO<sub>2</sub>@PDA system was investigated in vitro and in vivo. The obtained results show that after 48 h, twice as much MTX (cumulative amount) is released at pH 5.5 than at pH 7.4. This suggests that the MTX-mSiO<sub>2</sub>@PDA system exhibits a good pH sensitivity. In vitro local percutaneous administration experiments revealed that the cumulative amount of MTX transferred from MTX-mSiO<sub>2</sub>@PDA to pH 5.0 receptor fluid through the whole skin was approximately three times greater than the amount transferred to pH 7.4 receptor fluid after 24 h. Moreover, in vivo experiments conducted on a complete induced arthritis (CIA) model in DBA/1 mice demonstrated that the thickness of a mouse’s toes decreases to nearly 65% of the initial level after 27 days of local percutaneous MTX-mSiO<sub>2</sub>@PDA administration. Compared to the mice directly injected with MTX, those administered with MTX-mSiO<sub>2</sub>@PDA by local percutaneous application exhibit much lower toe thickness deviation, which indicates that the latter group experiences a better cure stability. Overall, these results demonstrate that the local percutaneous administration of MTX delivery systems characterized by nano-controlled release may play an important role in RA therapy.
format	article
author	Tingting Guo Xu Kang Sifan Ren Xianjin Ouyang Mingming Chang
author_facet	Tingting Guo Xu Kang Sifan Ren Xianjin Ouyang Mingming Chang
author_sort	Tingting Guo
title	Construction of a Nano-Controlled Release Methotrexate Delivery System for the Treatment of Rheumatoid Arthritis by Local Percutaneous Administration
title_short	Construction of a Nano-Controlled Release Methotrexate Delivery System for the Treatment of Rheumatoid Arthritis by Local Percutaneous Administration
title_full	Construction of a Nano-Controlled Release Methotrexate Delivery System for the Treatment of Rheumatoid Arthritis by Local Percutaneous Administration
title_fullStr	Construction of a Nano-Controlled Release Methotrexate Delivery System for the Treatment of Rheumatoid Arthritis by Local Percutaneous Administration
title_full_unstemmed	Construction of a Nano-Controlled Release Methotrexate Delivery System for the Treatment of Rheumatoid Arthritis by Local Percutaneous Administration
title_sort	construction of a nano-controlled release methotrexate delivery system for the treatment of rheumatoid arthritis by local percutaneous administration
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/6fcdfd0277584f1dad57dd24216c4a7d
work_keys_str_mv	AT tingtingguo constructionofananocontrolledreleasemethotrexatedeliverysystemforthetreatmentofrheumatoidarthritisbylocalpercutaneousadministration AT xukang constructionofananocontrolledreleasemethotrexatedeliverysystemforthetreatmentofrheumatoidarthritisbylocalpercutaneousadministration AT sifanren constructionofananocontrolledreleasemethotrexatedeliverysystemforthetreatmentofrheumatoidarthritisbylocalpercutaneousadministration AT xianjinouyang constructionofananocontrolledreleasemethotrexatedeliverysystemforthetreatmentofrheumatoidarthritisbylocalpercutaneousadministration AT mingmingchang constructionofananocontrolledreleasemethotrexatedeliverysystemforthetreatmentofrheumatoidarthritisbylocalpercutaneousadministration
_version_	1718411081069625344

Construction of a Nano-Controlled Release Methotrexate Delivery System for the Treatment of Rheumatoid Arthritis by Local Percutaneous Administration

Ejemplares similares